In postmarketing experience through an antiretroviral pregnancy registry, more than 200 pregnancies with first-trimester exposure to efavirenz as part of a combination antiretroviral regimen have been reported with no specific malformation pattern.
Turule toomise järgselt on rasedusregistrisse viirustevastaste ravimite kasutamise kohta teatatud üle 200 rasedusest, kus puututi efavirensiga kokku esimesel trimestril osana viirustevastasest kombinatsioonravist ilma spetsiifiliste väärarengute tekketa.